That may surprise many American taxpayers. Moderna had $17.7 billion in revenue from vaccine sales in 2021 and predicted it would bring in at least $19 billion in 2022.
"Not only has it got this public-private partnership issue that's still hovering in the background with the NIH, it's also got all this, this private litigation that's going on, which could impact how it develops its future technologies in terms of other products outside of COVID," Tahir Amin, a co-executive director of I-MAK told Fox News in an interview.
"There was a significant amount of funding, as I said, to some $2.5 billion that the government gave to Moderna to kind of help them push the research and development along. Some of that research and some of the technology that goes into the vaccine was actually developed by, like I said, at the NIH.
American taxpayers will be paying for Covid for decades to come.
Drug companies that released the vaccines under Emergency Use Authorizations are exempt from these lawsuits.